Premium
Correlation of IgE antibody titer to Aspergillus fumigatus with decreased lung function in cystic fibrosis
Author(s) -
Nicolai Thomas,
Arleth Sissi,
Spaeth Anne,
BerteleHarms RoseMarie,
Harms H. Karsten
Publication year - 1990
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.1950080106
Subject(s) - allergic bronchopulmonary aspergillosis , medicine , aspergillus fumigatus , cystic fibrosis , immunology , immunoglobulin e , aspergillus , aspergillosis , antibody , microbiology and biotechnology , biology
Obstructive pulmonary disease is a typical feature of cystic fibrosis (CF) and is often associated with bronchial hyperreactivity. Positive skin‐test reactions to Aspergillus fumigatus antigens are frequently seen even in nonatopic patients with CF. Full‐fledged allergic bronchopulmonary aspergillosis (ABPA) has been estimated to occur in 10% of patients with CF. The relationship between lung function and presence of IgE antibodies to Aspergillus antigens in patients without ABPA is not clear. In 148 outpatients with CF (aged 6–34 years) specific immunoglobulin E (IgE) to Aspergillus fumigatus antigens, basic lung‐function parameters, and bronchial response to salbutamol were measured. Multiple regression was performed for age, weight as percentile for actual height (indicating general condition), and Aspergillus RAST. Aspergillus IgE was present in 46% of patients; 19% had RAST class 3 or 4. Independent negative correlations of Aspergillus RAST with FEV 1 , FEF 50% , FEF 25% , RV, Chrispin Norman score, and sRaw (P<0.05) were found. Bronchodilator sensitivity did not correlate significantly with age and weight percentile. However, Aspergillus RAST did correlate significantly with bronchodilator response measured by sRaw ( P <0.05). High titers of Aspergillus RAST might serve as a selective criterion for patients to be included in future studies evaluating broncholytic or antiphlogistic therapies. Pediatr Pulmonol 1990; 8:12‐15.